-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Cancer is a very common disease.
According to the 2020 global cancer burden data released by the World Health Organization's International Agency for Research on Cancer (IARC), there will be 19.
29 million new cancer cases worldwide in 2020, and it is estimated that by 2022 This number will reach 20.
2 million annually
.
Among them, China, as a country with a large population, has a high number of new cancers, reaching 4.
57 million, accounting for 23.
7% of the world
.
At present, there is a huge unmet clinical treatment demand for the huge tumor patient population
.
According to Frost & Sullivan, the global antitumor drug market will reach US$150.
3 billion in 2020, and is expected to reach US$209.
9 billion by 2022, with a compound annual growth rate of 15.
2% from 2020 to 2025
.
Considerable market prospects are attracting many multinational pharmaceutical companies to invest in innovative tumor drugs and treatment plans
.
On April 5th, GE Healthcare and Elekta officially announced that they have signed a commercial cooperation agreement in the field of radiation oncology to jointly provide medical institutions around the world with comprehensive solutions from diagnosis to treatment to meet the needs of cancer patients.
Radiation therapy needs of patients
.
Novartis is undergoing a major transformation.
On April 4, Novartis CEO Vas Narasimhan said that with a new organizational structure and operating model, the future will focus on strengthening the research and development and commercialization of innovative drugs to help Novartis maintain sustained high growth
.
Among them, in terms of organizational structure, Novartis will integrate the two business departments of pharmaceuticals and oncology into a unified innovative medicine department
.
Dr.
Susanne Schaffert, president of Novartis Oncology, will also be leaving Novartis due to changes in the company's overall structure
.
On April 1, Daiichi Sankyo (China) announced that it has signed an agreement with Chongqing Yaoyou to transfer the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company that produces the preparations.
The transfer is expected to be completed by the end of August this year.
.
In the fierce international market competition, the company focuses on the oncology field by divesting non-core businesses
.
Prior to this, the company has successively optimized its business, such as transferring the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa
.
In addition, in March 2021, the company also reported that it plans to merge cardiovascular, anti-infective, and respiratory analgesia lines, mainly due to the impact of centralized procurement
.
From the perspective of the clinical pipelines of major pharmaceutical companies, tumors are also the focus of new drug research and development
.
For example, Roche’s 2021 annual report shows that the company has 80 clinical trials, of which the clinical trials of oncology remain high; Merck predicted in its financial report that there will be more than 90 potential new indications by 2028, the main products are K drugs, and Lynparza, a PARP inhibitor in cooperation with AZ, Lenvima, a multi-receptor tyrosine kinase inhibitor in cooperation with Eisai, and WELIREG, a first-in-class HIF-2α inhibitor
.
According to IQVIA statistics, the number of anti-tumor-related clinical trials initiated in 2021 hit a record high, an increase of about 70% compared with 2015
.
Recently, Guosheng Securities also sorted out AbbVie, Amgen, AstraZeneca, Bayer, Biogen, BMS, Gilead, GSK, Johnson & Johnson, Eli Lilly, Moderna, Merck, Novo Nordisk, Novartis, Pfizer, Regeneration 19 multinational pharmaceutical companies including Yuan, Roche, Sanofi and Takeda are in the clinical development stage of drug candidates and product pipelines
.
Among them, the tumor R&D pipeline accounts for 45% of the total R&D pipeline; from the perspective of the number of products under research, the number of anti-tumor products under research in the world will reach 2,226 in 2021, accounting for 37%
.
From the perspective of companies with rich oncology pipelines, four multinational giants, BMS, Merck, Roche, and Novartis, occupy half of the oncology R&D field
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
According to the 2020 global cancer burden data released by the World Health Organization's International Agency for Research on Cancer (IARC), there will be 19.
29 million new cancer cases worldwide in 2020, and it is estimated that by 2022 This number will reach 20.
2 million annually
.
Among them, China, as a country with a large population, has a high number of new cancers, reaching 4.
57 million, accounting for 23.
7% of the world
.
At present, there is a huge unmet clinical treatment demand for the huge tumor patient population
.
According to Frost & Sullivan, the global antitumor drug market will reach US$150.
3 billion in 2020, and is expected to reach US$209.
9 billion by 2022, with a compound annual growth rate of 15.
2% from 2020 to 2025
.
Considerable market prospects are attracting many multinational pharmaceutical companies to invest in innovative tumor drugs and treatment plans
.
On April 5th, GE Healthcare and Elekta officially announced that they have signed a commercial cooperation agreement in the field of radiation oncology to jointly provide medical institutions around the world with comprehensive solutions from diagnosis to treatment to meet the needs of cancer patients.
Radiation therapy needs of patients
.
Novartis is undergoing a major transformation.
On April 4, Novartis CEO Vas Narasimhan said that with a new organizational structure and operating model, the future will focus on strengthening the research and development and commercialization of innovative drugs to help Novartis maintain sustained high growth
.
Among them, in terms of organizational structure, Novartis will integrate the two business departments of pharmaceuticals and oncology into a unified innovative medicine department
.
Dr.
Susanne Schaffert, president of Novartis Oncology, will also be leaving Novartis due to changes in the company's overall structure
.
On April 1, Daiichi Sankyo (China) announced that it has signed an agreement with Chongqing Yaoyou to transfer the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company that produces the preparations.
The transfer is expected to be completed by the end of August this year.
.
In the fierce international market competition, the company focuses on the oncology field by divesting non-core businesses
.
Prior to this, the company has successively optimized its business, such as transferring the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa
.
In addition, in March 2021, the company also reported that it plans to merge cardiovascular, anti-infective, and respiratory analgesia lines, mainly due to the impact of centralized procurement
.
From the perspective of the clinical pipelines of major pharmaceutical companies, tumors are also the focus of new drug research and development
.
For example, Roche’s 2021 annual report shows that the company has 80 clinical trials, of which the clinical trials of oncology remain high; Merck predicted in its financial report that there will be more than 90 potential new indications by 2028, the main products are K drugs, and Lynparza, a PARP inhibitor in cooperation with AZ, Lenvima, a multi-receptor tyrosine kinase inhibitor in cooperation with Eisai, and WELIREG, a first-in-class HIF-2α inhibitor
.
According to IQVIA statistics, the number of anti-tumor-related clinical trials initiated in 2021 hit a record high, an increase of about 70% compared with 2015
.
Recently, Guosheng Securities also sorted out AbbVie, Amgen, AstraZeneca, Bayer, Biogen, BMS, Gilead, GSK, Johnson & Johnson, Eli Lilly, Moderna, Merck, Novo Nordisk, Novartis, Pfizer, Regeneration 19 multinational pharmaceutical companies including Yuan, Roche, Sanofi and Takeda are in the clinical development stage of drug candidates and product pipelines
.
Among them, the tumor R&D pipeline accounts for 45% of the total R&D pipeline; from the perspective of the number of products under research, the number of anti-tumor products under research in the world will reach 2,226 in 2021, accounting for 37%
.
From the perspective of companies with rich oncology pipelines, four multinational giants, BMS, Merck, Roche, and Novartis, occupy half of the oncology R&D field
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
